BNOX Bionomics ADS
3,029
$0.9878
$0.0278
(2.90%)
| Watchers | 3,029 |
| 52-Wk Low | $0.84 |
| 52-Wk High | $6.41 |
| Market Cap | $10.56M |
| Volume | 3.00 |
| 52-Wk High | $6.41 |
| 52-Wk Low | $0.84 |
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress DisorderGlobe Newswire • about 2 months ago
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over...
Share to Feed
Bionomics Limited (NASDAQ:BNOX Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest...
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel...
Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug...
The Company will provide an update on its leading asset BNC210 and their partnership strategyADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq...